DuPont Beat for a Fifth Straight Quarter — and Veralto's Multiple Values DuPont's Water Franchise Above Its Entire Market Cap

DuPont reported third-quarter 2026 results before the open on Nov. 3, and the shares rose 8.6% that session. Sales of $1,868 million grew 4% with organic sales up 5%, operating EBITDA rose 8% to $469 million, and adjusted EPS of $2.09 beat the $1.87 consensus. The operating engine is real but smaller than the headline: DuPont cut quarterly interest expense from $84 million to $40 million as cash built up after the separation, which at a 20% tax rate is roughly $0.26 of the $0.80 increase in adjusted EPS, and published call summaries put comparable adjusted EPS growth nearer 31%. DuPont's own full-year guide frames 2026 adjusted EPS growth at 21% to 22% against prior-year pro forma, so reconciling the headline against the company's own framing is the first job an investor has to do.

Healthcare & Water Technologies is no longer a rounding error inside DuPont. It generated $3,233 million of sales in 2025 against $2,976 million in 2024 and $2,919 million in 2023, with operating EBITDA of $972 million, $844 million and $866 million across those three years. Margin has climbed from 28.4% in 2024 to 30.1% in 2025 and 30.4% in the third quarter of 2026, a level that sits well above Veralto's 25.6% adjusted operating margin in its own third quarter. What is growing inside the segment is water: DuPont attributed third-quarter strength to industrial water, semiconductor and specialty markets, and pointed to reverse osmosis and ion exchange demand in industrial and municipal water as the driver of continued growth in 2026.

This is arithmetic, not argument, and it uses two published numbers. Veralto ended Oct. 29, 2026 on an enterprise value of $29.7 billion against trailing EBITDA of about $1.35 billion, which is 21.6 times. DuPont's Healthcare & Water Technologies earned $972 million of operating EBITDA in 2025. Apply Veralto's multiple to that one segment and it is worth roughly $21 billion, which is more than DuPont's entire $20.4 billion market capitalization and almost exactly its $21.8 billion enterprise value. The residual, a Diversified Industrials business with about $3.6 billion of 2025 sales and $655 million of operating EBITDA in nine months of 2026, is being valued at close to one times EBITDA.

The caveats are real. Healthcare & Water Technologies also contains healthcare packaging, which would not earn a water multiple; Veralto's returns and mix are not identical to DuPont's; and DuPont's water growth is not disclosed, so no one can confirm the segment deserves the same rating. But the gap is an order of magnitude larger than the caveats:the market is paying close to nothing for a $3.6 billion-revenue business earning 24% margins while handing a full water multiple to a segment whose size nobody will disclose.

Read that table the way the market does and the read-across stops being a surprise. Veralto and Ecolab carry the premium multiples, and both earned it by disclosing water growth tied to digital infrastructure: Veralto raised full-year core sales guidance to 4.2% to 4.5% and attributed Water Quality strength to North American digital infrastructure investment and water reuse needs, while Ecolab grew revenue 12.7%. DuPont guides to the same 4.5% organic growth as Veralto, at a segment margin Veralto does not have, on16.9 times EBITDA against Veralto's 21.6 times. The spread is not about growth.

Three things would close the gap, and only one of them requires a transaction. Publishing Water Technologies revenue, growth and margin would let the market value the segment without any deal. Reversing the January 2025 decision to retain Water would force a sum-of-the-parts re-rating that the current structure prevents. And with net debt down $1.04 billion in nine months to roughly 0.8 times guided operating EBITDA, DuPont could fund a separation without stretching its balance sheet. Management has said the retained Water business gives it strategic flexibility over time; that flexibility is the option an investor is being paid nothing for.

The bull case for DuPont is sometimes written as a PFAS pricing story. The filings do not support that reading. DuPont is not a PFAS manufacturer; PFAS is a liability on its balance sheet, and 2026 has been the year that liability was converted into scheduled, largely reserved cash outflows. The Sept. 10, 2026 North Carolina agreement resolves claims over the Fayetteville Works with the state and 11 local entities for $455 million payable over 15 years, with a net present value of roughly $355 million shared by DuPont, Chemours and Corteva. DuPont's pre-tax present value share is about $126 million, and 44% of that is reimbursable by Qnity after the separation.

The contagion test is instructive. Chemours carries the same PFAS history with a different balance sheet: $13.79 a share, an enterprise value of $5.4 billion against a $2.1 billion market capitalization, trailing EBITDA of essentially nothing, and trailing diluted EPS of negative $1.12, with its Advanced Performance Materials unit selling Nafion and other membranes. DuPont's PFAS obligations are immaterial against its cash generation; Chemours' are existential. That distinction is the entire difference between the two multiples, and it is why DuPont's discount to Veralto cannot be explained by PFAS risk alone.

DuPont's water growth is not a self-contained story; it sits between membrane makers who set the price and fab owners who set the volume. Upstream, Nitto Denko owns Hydranautics, which launched a fouling-resistant reverse osmosis membrane on Sept. 7, 2026 and competes directly with DuPont's reverse osmosis and ultrafiltration lines, and Toray runs a spiral-wound membrane element business spanning reverse osmosis, nanofiltration, ultrafiltration and membrane bioreactors. Downstream, Kurita Water Industries builds ultrapure water production systems for semiconductor fabs and reported business profit up 12.7% for the year ended March 31, 2026, and the fabs themselves are the volume: SK hynix approved roughly KRW 54 trillion, about $38.1 billion, of new DRAM and NAND capacity in Yongin and Cheongju on Aug. 7, 2026.

The correct conclusion is not that DuPont's water franchise is fake. It is that DuPont sits in the middle of the chain, selling a consumable into a capital cycle it does not control, against substitute suppliers with cheaper equity and more balance-sheet room. That is worth a membrane multiple, not a water-infrastructure multiple. The gap to Veralto closes on disclosure and structure, not on a better position in the chain, and DuPont will never own the chain the way a systems integrator does.

Netting it out, DuPont is no longer a legacy chemicals multiple, and the case for owning it is no longer that the market has not noticed the water franchise. The market has noticed. What it has not done is pay for it, because nobody can size it. The evidence that it deserves paying for is a 30.4% segment margin, reverse osmosis and ion exchange demand cited as the 2026 driver, a balance sheet that shed $1.04 billion of net debt in nine months, and a PFAS overhang small enough to dismiss. The stock works if management publishes the segment or separates it, and it is worth far less if DuPont simply keeps buying back stock at 17.8 times forward earnings while the water franchise stays invisible.